Ketamine One Announces Virtual Reality R&D Program

Ketamine One this week announced that its MindScape facility in Houston has launched a research and development program to study the use of immersive virtual reality (IVR) to enhance patients’ ketamine-assisted treatments.

The company said in a news release that its goal is to eventually deploy the IVR platform across its entire network of clinics across North America. In the meantime, through its recently acquired KGK Science division, Ketamine One plans to launch clinical studies later this year to further explore IVR and its potential for improving patient outcomes.

“The launch of our IVR therapy at MindScape is the first step towards what we believe is a potential paradigm shift for ketamine-assisted therapies and the future of psychedelic-based therapies,” Adam Deffett, vice president of capital markets for Ketamine One. “We are excited to see how this enhances the patient experience and expand the use of these treatments to our other clinics across North America.”

The company is also working on integrated system experience that incorporates wearable technologies that enable clinicians to personalize treatments and identify and respond to changes in patients’ wellbeing.